The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Male
Humans
Prostatic Neoplasms, Castration-Resistant
/ diagnostic imaging
Prostate-Specific Antigen
Treatment Outcome
Fluorodeoxyglucose F18
Prospective Studies
Prostate
/ pathology
Dipeptides
/ therapeutic use
Heterocyclic Compounds, 1-Ring
/ therapeutic use
Lutetium
/ therapeutic use
Retrospective Studies
68Ga-PSMA-11 PET
PSMA RLT
TheraP
mCRPC
metastatic castration-resistant prostate cancer
prostate-specific membrane antigen targeted radioligand therapy
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
19
12
2022
revised:
24
03
2023
medline:
3
8
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has shown encouraging results for treatment of metastatic castration-resistant prostate cancer (mCRPC) in the prospective, multicenter, randomized phase II TheraP study. The inclusion criteria for that study comprised a pretherapeutic
Identifiants
pubmed: 37290796
pii: jnumed.122.265346
doi: 10.2967/jnumed.122.265346
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Fluorodeoxyglucose F18
0Z5B2CJX4D
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
Lutetium
5H0DOZ21UJ
Types de publication
Clinical Trial, Phase II
Randomized Controlled Trial
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1252-1258Informations de copyright
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.